Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-03-13

METalmark

Phase 1/2 Active not recruiting

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-03-13

PolyDamas

Phase 1/2 Active not recruiting

71 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-03-13

COCOON

Phase 2 Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-03-13

KaRAnaSa

Phase 1/2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-02-25

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-02-13

PALOMA-2

Phase 2 Recruiting

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-02-05

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-01-16

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-01-16

COPERNICUS

Phase 2 Recruiting

480 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05801029 2025-12-09

OSTARA

Phase 2 Active not recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06816992 2025-03-20

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Phase 1 Recruiting

76 enrolled

Other solid neoplasmThoracic

Solid Tumors

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

Chrysalis-2

METalmark

PolyDamas

COCOON

KaRAnaSa

PAPILLON

PALOMA-2

MARIPOSA-2

MARIPOSA

CHRYSALIS

COPERNICUS

OSTARA

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors